Baidu
map

Lab Invest: 乳突状肾细胞癌趋化素、IL-8和CXCL16可以促进单核细胞募集和分化成泡沫巨噬细胞

2017-08-06 AlexYang MedSci原创

乳突状肾细胞癌(pRCC)是肾细胞癌的第二大常见类型。唯一的有效治疗Prcc的方法为根治性外科切除术。如果疾病发生扩散,化疗或者放疗都将不在产生治疗效果,因此对Prcc更进一步的研究非常重要。从组织病理上来说,pRCC是通过乳突的生长模式,即泡沫细胞表型的巨噬细胞焦点聚集。在其他类型的癌症中,在癌症生长和进展时,肿瘤相关的巨噬细胞的清楚的角色已经报道。尽管泡沫状巨噬细胞的出现是pRCC肿瘤的一个组

乳突状肾细胞癌(pRCC)是肾细胞癌的第二大常见类型。唯一的有效治疗Prcc的方法为根治性外科切除术。如果疾病发生扩散,化疗或者放疗都将不在产生治疗效果,因此对Prcc更进一步的研究非常重要。从组织病理上来说,pRCC是通过乳突的生长模式,即泡沫细胞表型的巨噬细胞焦点聚集。在其他类型的癌症中,在癌症生长和进展时,肿瘤相关的巨噬细胞的清楚的角色已经报道。尽管泡沫状巨噬细胞的出现是pRCC肿瘤的一个组织病理学标记,而关于它们在pRCC生物学中的作用却所知甚少。

最近,有研究人员为了研究pRCC肿瘤和骨髓细胞的互作关系,从pRCC组织中建立了原代培养。研究发现,人类pRCC细胞可以分泌趋化因子IL-8、CXCL16和趋化素,并且这些因子可以吸引体外试验中的人类单核细胞。来自癌症基因组数据库的RNSseq数据确认了这些因子在pRCC组织中高表达。pRCC培养基的条件培养基诱导了人类单核细胞向M2巨噬细胞的转换。在扩展的培养基中,这些巨噬细胞变大且满载液体,即在pRCC组织发现的泡沫状细胞形态。最后,研究人员指出,这些结果第一次表明了pRCC原发性肿瘤细胞可以分泌吸引和促使单核细胞分化成具有泡沫细胞组织学特点的抗炎症肿瘤相关巨噬细胞的因子。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1783986, encodeId=49a01e83986ed, content=<a href='/topic/show?id=aa8d553574' target=_blank style='color:#2F92EE;'>#CXCL1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5535, encryptionId=aa8d553574, topicName=CXCL1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Mon Jan 08 19:59:00 CST 2018, time=2018-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050807, encodeId=2880205080e70, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Sep 27 05:59:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978530, encodeId=ace919e8530b4, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sat Apr 21 09:59:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299108, encodeId=13e612991086a, content=<a href='/topic/show?id=2b85362063c' target=_blank style='color:#2F92EE;'>#单核细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36206, encryptionId=2b85362063c, topicName=单核细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=daa8281, createdName=雕雕, createdTime=Tue Aug 08 11:59:00 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625990, encodeId=e01c16259904c, content=<a href='/topic/show?id=cb38968469' target=_blank style='color:#2F92EE;'>#IL-8#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9684, encryptionId=cb38968469, topicName=IL-8)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a31920946979, createdName=respect, createdTime=Tue Aug 08 11:59:00 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230838, encodeId=f1d623083874, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sun Aug 06 21:19:04 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230829, encodeId=2e8f23082964, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Sun Aug 06 21:12:49 CST 2017, time=2017-08-06, status=1, ipAttribution=)]
    2018-01-08 wetgdt
  2. [GetPortalCommentsPageByObjectIdResponse(id=1783986, encodeId=49a01e83986ed, content=<a href='/topic/show?id=aa8d553574' target=_blank style='color:#2F92EE;'>#CXCL1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5535, encryptionId=aa8d553574, topicName=CXCL1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Mon Jan 08 19:59:00 CST 2018, time=2018-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050807, encodeId=2880205080e70, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Sep 27 05:59:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978530, encodeId=ace919e8530b4, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sat Apr 21 09:59:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299108, encodeId=13e612991086a, content=<a href='/topic/show?id=2b85362063c' target=_blank style='color:#2F92EE;'>#单核细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36206, encryptionId=2b85362063c, topicName=单核细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=daa8281, createdName=雕雕, createdTime=Tue Aug 08 11:59:00 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625990, encodeId=e01c16259904c, content=<a href='/topic/show?id=cb38968469' target=_blank style='color:#2F92EE;'>#IL-8#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9684, encryptionId=cb38968469, topicName=IL-8)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a31920946979, createdName=respect, createdTime=Tue Aug 08 11:59:00 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230838, encodeId=f1d623083874, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sun Aug 06 21:19:04 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230829, encodeId=2e8f23082964, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Sun Aug 06 21:12:49 CST 2017, time=2017-08-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1783986, encodeId=49a01e83986ed, content=<a href='/topic/show?id=aa8d553574' target=_blank style='color:#2F92EE;'>#CXCL1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5535, encryptionId=aa8d553574, topicName=CXCL1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Mon Jan 08 19:59:00 CST 2018, time=2018-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050807, encodeId=2880205080e70, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Sep 27 05:59:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978530, encodeId=ace919e8530b4, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sat Apr 21 09:59:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299108, encodeId=13e612991086a, content=<a href='/topic/show?id=2b85362063c' target=_blank style='color:#2F92EE;'>#单核细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36206, encryptionId=2b85362063c, topicName=单核细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=daa8281, createdName=雕雕, createdTime=Tue Aug 08 11:59:00 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625990, encodeId=e01c16259904c, content=<a href='/topic/show?id=cb38968469' target=_blank style='color:#2F92EE;'>#IL-8#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9684, encryptionId=cb38968469, topicName=IL-8)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a31920946979, createdName=respect, createdTime=Tue Aug 08 11:59:00 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230838, encodeId=f1d623083874, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sun Aug 06 21:19:04 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230829, encodeId=2e8f23082964, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Sun Aug 06 21:12:49 CST 2017, time=2017-08-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1783986, encodeId=49a01e83986ed, content=<a href='/topic/show?id=aa8d553574' target=_blank style='color:#2F92EE;'>#CXCL1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5535, encryptionId=aa8d553574, topicName=CXCL1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Mon Jan 08 19:59:00 CST 2018, time=2018-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050807, encodeId=2880205080e70, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Sep 27 05:59:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978530, encodeId=ace919e8530b4, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sat Apr 21 09:59:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299108, encodeId=13e612991086a, content=<a href='/topic/show?id=2b85362063c' target=_blank style='color:#2F92EE;'>#单核细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36206, encryptionId=2b85362063c, topicName=单核细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=daa8281, createdName=雕雕, createdTime=Tue Aug 08 11:59:00 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625990, encodeId=e01c16259904c, content=<a href='/topic/show?id=cb38968469' target=_blank style='color:#2F92EE;'>#IL-8#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9684, encryptionId=cb38968469, topicName=IL-8)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a31920946979, createdName=respect, createdTime=Tue Aug 08 11:59:00 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230838, encodeId=f1d623083874, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sun Aug 06 21:19:04 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230829, encodeId=2e8f23082964, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Sun Aug 06 21:12:49 CST 2017, time=2017-08-06, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1783986, encodeId=49a01e83986ed, content=<a href='/topic/show?id=aa8d553574' target=_blank style='color:#2F92EE;'>#CXCL1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5535, encryptionId=aa8d553574, topicName=CXCL1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Mon Jan 08 19:59:00 CST 2018, time=2018-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050807, encodeId=2880205080e70, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Sep 27 05:59:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978530, encodeId=ace919e8530b4, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sat Apr 21 09:59:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299108, encodeId=13e612991086a, content=<a href='/topic/show?id=2b85362063c' target=_blank style='color:#2F92EE;'>#单核细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36206, encryptionId=2b85362063c, topicName=单核细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=daa8281, createdName=雕雕, createdTime=Tue Aug 08 11:59:00 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625990, encodeId=e01c16259904c, content=<a href='/topic/show?id=cb38968469' target=_blank style='color:#2F92EE;'>#IL-8#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9684, encryptionId=cb38968469, topicName=IL-8)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a31920946979, createdName=respect, createdTime=Tue Aug 08 11:59:00 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230838, encodeId=f1d623083874, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sun Aug 06 21:19:04 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230829, encodeId=2e8f23082964, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Sun Aug 06 21:12:49 CST 2017, time=2017-08-06, status=1, ipAttribution=)]
    2017-08-08 respect
  6. [GetPortalCommentsPageByObjectIdResponse(id=1783986, encodeId=49a01e83986ed, content=<a href='/topic/show?id=aa8d553574' target=_blank style='color:#2F92EE;'>#CXCL1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5535, encryptionId=aa8d553574, topicName=CXCL1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Mon Jan 08 19:59:00 CST 2018, time=2018-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050807, encodeId=2880205080e70, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Sep 27 05:59:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978530, encodeId=ace919e8530b4, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sat Apr 21 09:59:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299108, encodeId=13e612991086a, content=<a href='/topic/show?id=2b85362063c' target=_blank style='color:#2F92EE;'>#单核细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36206, encryptionId=2b85362063c, topicName=单核细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=daa8281, createdName=雕雕, createdTime=Tue Aug 08 11:59:00 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625990, encodeId=e01c16259904c, content=<a href='/topic/show?id=cb38968469' target=_blank style='color:#2F92EE;'>#IL-8#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9684, encryptionId=cb38968469, topicName=IL-8)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a31920946979, createdName=respect, createdTime=Tue Aug 08 11:59:00 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230838, encodeId=f1d623083874, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sun Aug 06 21:19:04 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230829, encodeId=2e8f23082964, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Sun Aug 06 21:12:49 CST 2017, time=2017-08-06, status=1, ipAttribution=)]
    2017-08-06 清风拂面

    谢谢分享,学习了

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1783986, encodeId=49a01e83986ed, content=<a href='/topic/show?id=aa8d553574' target=_blank style='color:#2F92EE;'>#CXCL1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5535, encryptionId=aa8d553574, topicName=CXCL1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Mon Jan 08 19:59:00 CST 2018, time=2018-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050807, encodeId=2880205080e70, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Sep 27 05:59:00 CST 2017, time=2017-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978530, encodeId=ace919e8530b4, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sat Apr 21 09:59:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299108, encodeId=13e612991086a, content=<a href='/topic/show?id=2b85362063c' target=_blank style='color:#2F92EE;'>#单核细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36206, encryptionId=2b85362063c, topicName=单核细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=daa8281, createdName=雕雕, createdTime=Tue Aug 08 11:59:00 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625990, encodeId=e01c16259904c, content=<a href='/topic/show?id=cb38968469' target=_blank style='color:#2F92EE;'>#IL-8#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9684, encryptionId=cb38968469, topicName=IL-8)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a31920946979, createdName=respect, createdTime=Tue Aug 08 11:59:00 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230838, encodeId=f1d623083874, content=谢谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Sun Aug 06 21:19:04 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230829, encodeId=2e8f23082964, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Sun Aug 06 21:12:49 CST 2017, time=2017-08-06, status=1, ipAttribution=)]
    2017-08-06 楠博One

    学习谢谢分享

    0

相关资讯

JAMA Oncology:高风险肾细胞癌肾切除术后Girentuximab辅助治疗

Girentuximab是一种结合了碳酸酐酶Ⅸ的嵌合式单克隆抗体,碳酸酐酶Ⅸ是肾透明细胞癌(ccRCC)细胞表明广泛表达的糖蛋白。在Ⅱ期研究中已验证了其安全性和活性,从而推进了其作为高风险ccRCC辅助治疗药物的进一步研究。JAMA Oncology近期发表了一篇文章,评估了Girentuximab辅助治疗对局部完全切除的高风险ccRCC患者无病生存(DFS)以及总生存(OS)的影响。

JCO:晚期乳头状肾细胞癌患者使用savolitinib的生物标志物(II期试验)

晚期乳头状肾细胞癌(PRCC)的治疗选择是有限的。其可能涉及的MET通路的激活,例如,通过基因扩增或基因突变。Savolitinib(AZD6094, HMPL-504,沃利替尼)是一种高选择性MET酪氨酸激酶抑制剂。近期发表在JCO上的一项研究中,研究人员报告了一个单臂、多中心、II期研究,该研究根据MET状态评估了在PRCC患者中Savolitinib的安全性和疗效。被诊断为局部晚期或转移性乳

Sci Rep:较低的平均血小板体积可以预测肾细胞癌不良预后

之前的研究发现,改变的的平均血小板体积(MPV)在几种恶性肿瘤中存在。值得注意的是,MPV在肾细胞癌(RCC)中预后评估的价值还没有达成共识。最近,有研究人员调查了MPV值作为一个RCC预后因子的可能性。该回顾性的研究招募了在2009年1月到2009年12月的306名连续的RCC病人。研究人员对MPV和临床病理学特性的关系进行了分析,并利用卡普兰-梅尔分析方法和Cox回归评估了MPV的预后影响。研

Oncogene:PDZK-1可以通过抑制SHP-1的磷酸化抑制肾细胞癌的发生和发展

肾细胞癌(RCC)是最具有侵略性泌尿外科癌症之一,然而,RCC致癌作用的的机制到目前为止仍旧不清楚。最近,研究人员通过利用基因表达分析和功能聚类发现,包含PDZ结构域蛋白1(PDZK1)在人类透明细胞肾细胞癌(ccRCC)中表达下调,该现象在一些相互独立的公共ccRCC数据库中同样得到了鉴证。另外,通过在ccRCC细胞系中PDZK1的超表达和敲除,研究人员阐释了PDZK1可以抑制细胞增殖、细胞周期

JCO:Nivolumab联合Ipilimumab治疗转移性肾细胞癌

免疫检查点抑制剂联合治疗与单药治疗相比具有更强的抗肿瘤活性。Ⅰ期Checkmate 016研究主要评估Nivolumab联合Ipilimumab以及Nivolumab加一种酪氨酸激酶抑制剂治疗转移性肾细胞癌(mRCC)的有效性及安全性。JCO近期发表了一篇文章,报道了Nivolumab联合Ipilimumab组的安全性及有效性结果。

JCO:Nivolumab联合ipilimumab——转移性肾细胞癌患者的新福音?

如今越来越多的研究表明与单一疗法相比,联合免疫抑制剂的联合疗法表现出更强的抗肿瘤活性,如黑色素瘤的治疗。开放、平行对照、剂量递增、 I 期阶段的CheckMate研究评估了nivolumab加ipilimumab联合治疗、nivolumab加酪氨酸激酶抑制剂在转移性肾细胞癌中(mRCC)的安全性和疗效。nivolumab联合ipilimumab治疗的安全性和有效性如下文所示。

Baidu
map
Baidu
map
Baidu
map